hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its interim results for the six months ended 30 June 2023 on Tuesday 12 September 2023.
hVIVO introduces groundbreaking hMPV challenge model to hasten vaccine and therapy development against respiratory pathogen. Learn more here.
hVIVO uncovers rare subclinical myocarditis cases in RSV clinical trials, showcasing the power of human challenge models for early signal detection in drug development.
Discover how Venn Life Sciences navigated complex regulatory and technical challenges to help a Japanese biotech company scale production for US clinical trials seamlessly.
In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO
Discover how hVIVO’s hMPV challenge model is revolutionizing vaccine testing with high infection rates and accurate results. Learn more here.
hVIVO has unveiled its state-of-the-art outpatient facility in Whitechapel, London, marking a significant expansion in its clinical site services. This modern unit is designed to enhance the efficiency and effectiveness of vaccine and therapeutic studies, reflecting
Participate in paid clinical trials with FluCamp to contribute to medical breakthroughs and earn financial compensation. Learn how to get involved in these important studies.
Japan is considering human challenge trials to speed up vaccine development. This bold move could position the country at the forefront of medical research.
hVIVO partners with ILiAD Biotechnologies for Phase 3 human challenge trial on BPZE1, a promising whooping cough vaccine candidate, demonstrating leadership in advanced vaccine research.
Amid rising concerns over human metapneumovirus (hMPV) infections, hVIVO’s innovative challenge model offers hope for accelerated vaccine development.
hVIVO bolsters its clinical research capabilities with the €10 million acquisition of CRS Clinical Research Services Management GmbH, expanding its reach in Europe.
hVIVO plc, a leading CRO, collaborated with Shionogi for a successful Phase 2a RSV antiviral trial. Positive results show significant reduction in viral load.
hVIVO, a leader in pharmaceutical services, recently expanded its European footprint with the acquisition of two clinical trial units in Germany.
hVIVO plc partners with Inhalon Biopharma, Inc. to test inhaled IN-002 antiviral candidate using RSV Human Challenge Model. Trial set to commence in H2 2026.
hVIVO plc has acquired two Clinical Research Units from CRS, boosting its capabilities in conducting human challenge clinical trials and expanding services.
Explore the innovative world of field studies with FluCamp, revolutionising clinical research by bringing trials closer to real-life scenarios.
hVIVO plc partners with ILiAD Biotechnologies for Phase 3 trial of Bordetella pertussis vaccine, marking a significant milestone in preventing whooping cough.
hVIVO plc achieves milestone with £3.2 million hLAB contract, showcasing growth in laboratory services. Read about the company’s latest achievement here.
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.